Clovis licenses lung cancer programme from Avila for up to $209 million
This article was originally published in Scrip
Executive Summary
Avila Therapeutics could receive up to $209 million from Clovis Oncology under the two companies' agreement to develop and commercialise Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) programme.